CD33 and acute myeloid leukemia: However, both medical agencies (FDA and EMA) have used different labels, as the FDA indicates the use of GO for both newly diagnosed as well as relapsed or refractory (r/r) CD33-positive AML in adults, whereas the EMA indicates its use only for newly diagnosed AML [17,18,22,23].